Segall Bryant & Hamill LLC Lowers Stock Holdings in Alkermes plc $ALKS

Segall Bryant & Hamill LLC lowered its stake in Alkermes plc (NASDAQ:ALKS) by 4.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 585,769 shares of the company’s stock after selling 29,523 shares during the period. Segall Bryant & Hamill LLC’s holdings in Alkermes were worth $20,713,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Cullen Frost Bankers Inc. acquired a new stake in shares of Alkermes during the fourth quarter worth $28,000. Johnson Financial Group Inc. purchased a new position in Alkermes in the 3rd quarter valued at $31,000. UMB Bank n.a. grew its position in Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after buying an additional 446 shares during the last quarter. Salomon & Ludwin LLC increased its stake in Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after buying an additional 667 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Alkermes by 1,041.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock valued at $37,000 after buying an additional 1,208 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wells Fargo issued a Buy rating on Alkermes, providing a favorable view of the company’s outlook and potentially supporting investor confidence. Wells Fargo Gives a Buy Rating to Alkermes
• Positive Sentiment: JPMorgan raised its price target to $61, while Robert W. Baird reportedly expects the shares to rise. The targets indicate that some analysts see additional upside from current levels. JPMorgan Raises Alkermes Price Target Baird Analyst Expects Alkermes Stock to Rise
• Neutral Sentiment: Analyst opinions remain mixed, with Wells Fargo’s Buy stance contrasting with HC Wainwright’s Neutral rating. Alkermes also released its second-quarter 2026 earnings-call presentation, giving investors additional information to assess operating performance and its pipeline. Mixed Analyst Opinions on Alkermes Alkermes 2026 Second-Quarter Earnings Presentation
• Negative Sentiment: HC Wainwright significantly lowered its earnings outlook across multiple periods. Its Q3 2026 EPS estimate moved to a loss of $0.09 from a profit of $0.03, while its FY2026 estimate fell to a loss of $0.71 from a loss of $0.44. Forecasts also declined for FY2027 through FY2030, including FY2028 moving to a loss of $0.29 from earnings of $0.52 and FY2029 falling to $0.55 from $1.27. The firm maintained a Neutral rating, signaling weaker expected profitability and a more cautious long-term view.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALKS. Royal Bank Of Canada raised their target price on shares of Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 9th. Bank of America reissued an “underperform” rating on shares of Alkermes in a report on Monday, June 29th. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective (up from $43.00) on shares of Alkermes in a research report on Tuesday. UBS Group lifted their price objective on Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, TD Cowen boosted their target price on Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $54.56.

Alkermes Price Performance

Alkermes stock opened at $48.99 on Friday. The company has a market cap of $8.22 billion, a P/E ratio of 128.92 and a beta of 0.34. Alkermes plc has a one year low of $25.17 and a one year high of $55.67. The business has a fifty day moving average of $48.24 and a two-hundred day moving average of $38.17. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.70 and a current ratio of 2.30.

Insider Activity

In other news, Director Christopher I. Wright sold 2,000 shares of the stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $45.10, for a total value of $90,200.00. Following the completion of the transaction, the director owned 25,680 shares in the company, valued at $1,158,168. This trade represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $54.03, for a total transaction of $109,897.02. Following the completion of the sale, the executive vice president owned 227,490 shares of the company’s stock, valued at $12,291,284.70. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,102 shares of company stock worth $1,193,810 in the last 90 days. 4.59% of the stock is currently owned by corporate insiders.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.